for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Cardiovascular Systems Inc

CSII.OQ

Latest Trade

19.33USD

Change

--(--)

Today's Range

--

 - 

--

52 Week Range

19.25

 - 

48.27

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
19.33
Open
--
Volume
--
3M AVG Volume
5.45
Today's High
--
Today's Low
--
52 Week High
48.27
52 Week Low
19.25
Shares Out (MIL)
40.55
Market Cap (MIL)
811.01
Forward P/E
-46.92
Dividend (Yield %)
--

Next Event

Q2 2022 Cardiovascular Systems Inc Earnings Release

Latest Developments

More

Cardiovascular Systems, Inc. Initiates Voluntary Recall Of Wirion® Embolic Protection System

Cardiovascular Systems Inc Says Volume Of Procedures Involving Co's Products Has Been Adversely Impacted By Hospital Capacity Constraints

Cardiovascular Systems Reports Fiscal 2021 Q4 And Full Year Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Cardiovascular Systems Inc

Cardiovascular Systems, Inc. is a medical technology company, which is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed patented orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), which is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.

Industry

Medical Equipment & Supplies

Contact Info

1225 Old Highway 8 NW

ST. PAUL, MN

55112-6416

United States

+1.651.2591600

http://csi360.com/

Executive Leadership

Scott Raymond Ward

Chairman of the Board, President, Chief Executive Officer

Jeffrey S. Points

Chief Financial Officer

Rhonda J. Robb

Chief Operating Officer

Stephen J. Rempe

Chief Human Resource Officer

John M. Hastings

Executive Vice President - Operations and Technology

Key Stats

2.38 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2019

0.2K

2020

0.2K

2021

0.3K

2022(E)

0.3K
EPS (USD)

2019

-0.010

2020

-0.790

2021

-0.350

2022(E)

-0.426
Price To Earnings (TTM)
--
Price To Sales (TTM)
3.16
Price To Book (MRQ)
3.08
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.80
LT Debt To Equity (MRQ)
7.80
Return on Investment (TTM)
-6.82
Return on Equity (TTM)
-5.92

Latest News

Latest News

Device maker Cardiovascular Systems warns of hit to sales from Delta variant

Medical device maker Cardiovascular Systems Inc on Wednesday warned of lower-than-expected sales in the first quarter, as the Delta variant of the coronavirus threatens to dent the recovery in demand for non-urgent surgeries.

BRIEF-Cardiovascular Systems Says Entered Into Supply Agreement With Abrasive Technology

* CARDIOVASCULAR SYSTEMS - ON JUNE 19, ENTERED INTO SUPPLY AGREEMENT WITH ABRASIVE TECHNOLOGY - SEC FILING

BRIEF-Cardiovascular Systems Prices Public Offering Of Common Stock

* CARDIOVASCULAR SYSTEMS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Cardiovascular Systems Announces Proposed Public Offering Of Common Stock

* CARDIOVASCULAR SYSTEMS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Cardiovascular Systems Reports Fiscal 2020 Third-Quarter Financial Results

* CARDIOVASCULAR SYSTEMS, INC. REPORTS FISCAL 2020 THIRD-QUARTER FINANCIAL RESULTS

BRIEF-Cardiovascular Systems Says Withdrawing Financial Guidance For Full Fiscal Year Ending June 30, 2020

* CARDIOVASCULAR SYSTEMS INC - WITHDRAWING ITS FINANCIAL GUIDANCE FOR FULL FISCAL YEAR ENDING JUNE 30, 2020

BRIEF-Cardiovascular Systems Enteres Amendment To Loan And Security Agreement Dated March 31, 2017

* CARDIOVASCULAR SYSTEMS INC - ENTERED INTO FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED MARCH 31, 2017

BRIEF-Cardiovascular Systems Entered Into Amendment No. 2 To Supply Agreement & Amendment No. 2 To Product Schedule With Fresenius Kabi AB

* CARDIOVASCULAR SYSTEMS - ENTERED INTO AMENDMENT NO. 2 TO SUPPLY AGREEMENT & AMENDMENT NO. 2 TO PRODUCT SCHEDULE WITH FRESENIUS KABI AB

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up